In­novent claims two PhI­II wins for PC­SK9 an­ti­body, but non-Chi­na strat­e­gy re­mains un­clear

Much of the spot­light on Chi­nese biotech and Eli Lil­ly part­ner In­novent has fo­cused on its an­ti-PD-1 ef­forts, but on Thurs­day the com­pa­ny tout­ed a win in an­oth­er in­di­ca­tion.

In­novent re­port­ed two Phase III stud­ies for its an­ti-PC­SK9 an­ti­body, known as IBI306, hit their pri­ma­ry end­points ear­ly Thurs­day morn­ing. They’re the sec­ond and third reg­is­tra­tional stud­ies for the pro­gram and In­novent now plans to ap­proach Chi­nese reg­u­la­tors to sub­mit a new drug ap­pli­ca­tion some­time this year, the biotech said.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER